Which clinical trials show L‑citrulline or L‑arginine improving erectile dysfunction and what doses were used?
Executive summary
Two lines of clinical evidence support modest efficacy of nitric-oxide precursors for erectile dysfunction: a small single‑blind pilot trial found oral L‑citrulline 1.5 g/day improved erection hardness in men with mild ED, and randomized trials of oral L‑arginine—especially at higher daily doses—have shown benefit in vasculogenic or mild–moderate ED, with doses reported between ~1.5 g and 6 g daily in the reviewed literature [1] [2] [3]. Confidence is limited by small sample sizes, heterogeneous populations and formulations, and a lack of large, definitive randomized trials [4] [2].
1. The clearest positive trial: L‑citrulline 1.5 g/day in mild ED
A single‑blind, placebo‑controlled pilot study of 24 men with mild erectile dysfunction reported that one month of oral L‑citrulline at 1.5 g per day raised the erection hardness score from 3 to 4 in 50% of participants versus 8.3% on placebo, with no reported adverse events in the trial (Cormio et al.; Urology) [5] [1] [6]. The investigators justify citrulline use because it is converted to arginine in vivo and avoids first‑pass hepatic metabolism that limits oral arginine’s bioavailability [1].
2. L‑citrulline as adjunct or pilot evidence, not a first‑line proven therapy
Subsequent work has explored L‑citrulline in combination regimens and in animal models, and at least one randomized double‑blind crossover pilot studied L‑citrulline plus trans‑resveratrol in men using PDE‑5 inhibitors, reporting improvements in erectile function measures, but these are pilot data and the precise single‑agent dose–response in broader clinical populations remains underpowered and not fully standardized across trials [7] [8]. Reviews and clinical summaries highlight citrulline’s physiologic rationale but emphasize the thin clinical base and absence of large randomized safety trials [7] [4].
3. L‑arginine trials: doses vary, higher doses evaluated in vasculogenic ED
Randomized clinical trial evidence for L‑arginine is more numerous but heterogeneous: a 2019 systematic review and meta‑analysis pooled 10 randomized controlled trials (540 patients) and found arginine supplementation (doses reported across studies from about 1,500 mg to 5,000 mg daily) significantly improved erectile outcomes versus placebo [2]. More recently, a multicentre, double‑blind, randomized, placebo‑controlled trial specifically tested a relatively high dose of L‑arginine, 6 g/day for three months, in patients with vasculogenic ED (N ≈ 98 randomized), demonstrating the trial design but requiring reading of the full report for precise outcome magnitudes and subgroup effects [3].
4. Combination therapies and small incremental benefits
Meta‑analytic and narrative reviews note that L‑arginine has been tested both alone and in combination with other agents (yohimbine, pycnogenol, niacin, citrulline, PDE‑5 inhibitors), and that two trials combining arginine with PDE‑5 inhibitors showed small but statistically significant advantages over PDE‑5 inhibitor alone—suggesting possible additive physiology, though clinical impact varies by study and formulation [9] [2]. The systematic review underscores that many positive trials evaluated arginine as part of combination nutraceutical products, complicating attribution to arginine alone [2].
5. Limitations, safety signals and research gaps
The available trials are typically small, often short (weeks to months), and enroll men with mild to moderate or specific vasculogenic ED; generalizability to severe ED, long‑term outcomes, and population subgroups is uncertain [1] [2] [4]. Safety reporting has not revealed major signals in small trials, but reviewers and consumer health summaries caution that no large randomized safety trial exists for citrulline in ED and that citrulline or arginine combined with other vasodilators can cause clinically important blood‑pressure drops [4]. Mechanistic and preclinical work suggests plausible NO‑mediated and possibly PDE‑5–modulating effects, but some recent mechanistic claims require in vivo validation [10].
6. Bottom line for clinicians and researchers
Clinical trials support that oral L‑citrulline 1.5 g/day may help men with mild ED, and randomized evidence for L‑arginine shows benefit across doses roughly 1.5–5 g/day with at least one trial testing 6 g/day in vasculogenic ED; however, effect sizes are modest, evidence quality variable, and larger definitive trials are lacking [1] [2] [3]. Reviews recommend cautious consideration of arginine/citrulline as part of a broader treatment strategy rather than a replacement for guideline therapies, and they call for larger, well‑powered randomized trials to establish safety, optimal dosing, and which patients are most likely to benefit [2] [4].